Can radiomics signatures and machine learning methods reinforce the revived role of (18)F-NaF in metastatic bone disease?

放射组学特征和机器学习方法能否强化(18)F-NaF在转移性骨病中的复兴作用?

阅读:2

Abstract

OBJECTIVES: To evaluate whether radiomic features extracted from (18)F-NaF PET/CT scans, analyzed using machine learning (ML) methods, can improve the differentiation between true metastatic bone lesions (TP) and false-positive benign uptake (FP), thereby enhancing the diagnostic utility of (18)F-NaF PET/CT. METHODS: This retrospective study included 62 patients with known primary malignancies who underwent (18)F-NaF PET/CT. Lesions were classified as TP or FP based on consensus interpretation including follow-up. Patients were randomly split into training (n=41) and validation (n=21) groups. Radiomic features were extracted from PET images using LIFEx software. Feature selection (ANOVA, RFE) and ML model training (SVM, Random Forest, XGBoost) were performed. Model performance was evaluated using accuracy, specificity, sensitivity, and AUC, initially with a train/validation split and subsequently with 5-fold cross-validation incorporating feature engineering and hyperparameter tuning. Feature importance was assessed using SHAP. RESULTS: Significant differences in SUV(max) (p=0.006) and SUV(mean) (p=0.034) were observed between TP and FP lesions. Initial validation showed XGBoost performed best (AUC=0.78). After optimization and 5-fold cross-validation on the combined dataset (n=62), the tuned XGBoost model achieved the highest performance (Mean Accuracy: 85.7% ±2.9%, Mean AUC: 0.86), outperforming Random Forest (AUC: 0.79) and SVM (AUC: 0.74). SHAP analysis identified SUV(max), SUV(mean), Voxel Volume Num, GLRLM RLNU, and Skew. CONCLUSION: Radiomics-based machine learning classifiers, particularly XGBoost, demonstrated strong performance in distinguishing true metastatic from false-positive benign lesions on (18)F-NaF PET/CT. Integrating radiomics and ML can potentially improve the diagnostic accuracy and robustness of (18)F-NaF PET/CT for assessing bone metastases. Further validation in larger cohorts is warranted.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。